ReviewMolecular neurobiology2026
Mechanisms of Selective Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: Cortico-Striatal Circuitry, Glutamatergic Dysregulation, and Neuroplastic Constraints.
Review in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obsessive-compulsive disorder (OCD) is a chronic and disabling neuropsychiatric condition for which selective serotonin reuptake inhibitors (SSRIs) remain the first-line pharmacological treatment. Despite their widespread use, a substantial proportion of patients fail to achieve adequate symptom remission following appropriately dosed and prolonged SSRI therapy, highlighting the clinical challenge of treatment-resistant OCD. Traditional serotonin-centric models do not fully account for delayed therapeutic onset, incomplete response, or the frequent need for pharmacological augmentation. This review synthesizes current evidence examining the neurobiological mechanisms underlying SSRI response and resistance in OCD, with a particular focus on cortico-striato-thalamo-cortical (CSTC) circuit dysfunction, glutamatergic imbalance, and impaired neuroplasticity. The review discusses how SSRIs exert indirect effects on excitatory-inhibitory balance, synaptic remodeling, and intracellular signaling pathways, and why these downstream processes may fail in treatment-resistant individuals. Emerging roles of glutamatergic dysregulation, intracellular plasticity signaling deficits, and neuroinflammatory constraints are integrated into a unified mechanistic framework. The present review advances a conceptual framework in which treatment-resistant OCD may involve constraints on neuroplastic adaptation, such that serotonergic modulation alone is insufficient to induce durable circuit-level recalibration in a subset of patients. This model offers a potential biological rationale for augmentation strategies targeting dopaminergic, glutamatergic, and plasticity-related pathways, and underscores the need for mechanism-based, personalized therapeutic approaches. By reframing SSRI efficacy and failure at the circuit and systems level, this review aims to inform future translational research and guide more effective treatment strategies for refractory OCD.
Indexed as
Identifiers
42758451What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.